MMJ BioPharma’s noble pursuit of scientific advancement has been met with a series of inexplicable roadblocks and bureaucratic hurdles erected by the DEA. In 2018, the company dutifully applied for the necessary licenses to cultivate marijuana for research and development purposes, eagerly anticipating the opportunity to commence clinical trials that could yield life-changing treatments. Yet, despite meticulously following the DEA’s convoluted application process, MMJ BioPharma found itself trapped in a seemingly endless cycle of delays, obfuscation, and stonewalling.
Twenty patient associations from across northeastern Brazil are meeting in Fortaleza this month, inside a…
In 1968, a few joints I gave away left me facing the possibility of decades…
Here's the part that should worry every operator, investor, and vendor in the industry: this…
For one hash maker the clock starts at harvest, and the flower is in the…
Cannabis can absolutely take you somewhere that looks like a classic psychedelic experience. It just…
Researchers analyzing two ancient skeletons from Indonesia found dramatic dental wear and traces of arecoline,…